Vimarsana
Biggest News Aggregation in the World

Page 5 - Aim Leukemia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aim Leukemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aim Leukemia Today - Breaking & Trending Today

Curis Reports Second Quarter 2022 Financial Results and Business Update - Vimarsana News

Curis Reports Second Quarter 2022 Financial Results and Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) - Vimarsana News

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis to Present at 2022 Jefferies Global Healthcare Conference - Vimarsana News

Curis to Present at 2022 Jefferies Global Healthcare Conference

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA) - Vimarsana News

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Reports First Quarter 2022 Financial Results and Business Update - Vimarsana News

Curis Reports First Quarter 2022 Financial Results and Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...